Why JNJ Belongs in a Portfolio That Feels Too Heavy on AI

The AI rally has pushed a handful of tech names to valuations that leave little room for error. For portfolios that feel top-heavy on growth, the obvious fix is a barbell – pairing high-beta AI exposure with a steady compounder that can absorb drawdowns. Johnson & Johnson, on track to become the first pharmaceutical company to break $100bn in annual revenue by 2026, fits that role as well as any name in healthcare, according to a recent Seeking Alpha analysis.

The $100bn milestone would make JNJ the largest pharma group by top line, a fact that speaks to the breadth of its portfolio: pharmaceuticals, medical devices, and consumer health. That diversity matters when a single drug class runs into patent cliffs. JNJ's MedTech segment, which includes surgery, orthopedics, and vision, has been a consistent growth driver, and its pharma pipeline has enough near-term catalysts to sustain the revenue trajectory through the middle of the decade.

What JNJ offers that the AI darlings cannot is an earnings stream backed by recurring surgical procedures and prescription volumes – demand that does not vanish when interest rates stay high or when the next large language model fails to live up to the hype. The stock's beta is roughly half that of the Nasdaq 100. In a sell-off triggered by a Fed pivot or a rotation out of momentum, JNJ tends to lose less and recover faster. That is the barbell payoff.

None of this means JNJ is risk-free. The company faces headwinds from the Inflation Reduction Act's drug pricing provisions in the US and from biosimilar competition on its blockbuster Stelara. Litigation over talc liabilities continues to create headline noise, even if the financial hit has so far been manageable. The path to $100bn assumes steady execution across a sprawling organization – not a given in a sector where pipeline setbacks can erase years of growth in a single clinical trial readout.

AlphaScala's proprietary score of 57 out of 100 labels JNJ as Moderate, reflecting a balanced risk-reward profile. The score weighs valuation, earnings quality, and momentum against sector-specific risks like patent exposure and regulatory shifts. For a barbell strategy, that moderate rating is exactly what you want: enough upside to keep the position from being dead weight, enough downside protection to do its job when the speculative side of the portfolio gets hit.

The barbell argument works best when the growth leg – in this case, AI – is dominant but fragile. If the AI trade continues to run, JNJ will lag on a relative basis, it will still compound at a mid-single-digit earnings growth clip with a dividend yield above 3%. If AI corrects, JNJ's relative outperformance should offset a meaningful chunk of the portfolio loss. That asymmetry is the reason institutional allocators have long used healthcare as a stabilizer. With JNJ on the verge of a revenue milestone that no pharma company has reached, the case is stronger than most.

The next concrete check is the Q2 earnings report, due in July, where MedTech growth and pharma pipeline updates will either confirm the trajectory or raise questions. For anyone managing a portfolio that has ridden the AI wave hard, the question is not whether JNJ is an exciting stock – it is not – whether the barbell they are not using will cost them when the cycle turns.